PEN Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.…
Industry Peers
Medical DevicesKey Statistics
About Penumbra (NYSE: PEN)
›
Penumbra (NYSE: PEN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4,700 employees.
The shares were at 319.12 USD on 20 November 2026, up 14.6% over 52 weeks. Its 52-week range is 276.01 USD to 362.41 USD: the price is 11.9% below the high and 15.6% above the low.
At a market capitalisation of 12.58B USD, it trades at 80.4 times trailing earnings and 53.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 24.9, a premium of 223% for PEN.
Penumbra reports return on equity of 12.4%, an operating margin of 12.1% and revenue up 15.6% year over year.
It holds more cash than debt, a net cash position of 464.22M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 362.54 USD is 13.6% above the current price. The next earnings report is expected on 24 February 2027.